Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brandon-Luke Seagle

Obstetrics & Gynecology Americus, GA Medical Doctor

NPI 1609175272 CMS profile 722348

100 Plantation Ridge Dr, Americus, GA 31709

Open in the dashboard

General payments

$1,708

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandon-Luke Seagle of Americus, GA is reported in the CMS Open Payments database as having received $1,708 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $226 2
2024 General $115 5
2023 General $263 8
2022 General $471 11
2021 General $213 13
2020 General $219 10
2019 General $200 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon-Luke Seagle
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Brandon-Luke Seagle were reported at $226. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Brandon-Luke Seagle Obstetrics & Gynecology median Middle half National median
2019 $200 $172 $62–$391 $163
2020 $219 $94 $36–$222 $114
2021 $213 $136 $42–$369 $132
2022 $471 $160 $50–$433 $149
2023 $263 $169 $56–$423 $160
2024 $115 $152 $50–$371 $164
2025 $226 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $596 13 payments
  2. Astellas Pharma US Inc $518 17 payments
  3. Amgen Inc. $168 9 payments
  4. Medtronic USA, Inc. $55 1 payment
  5. Axonics Modulation Technologies, Inc. $53 3 payments
  6. AbbVie, Inc. $47 3 payments
  7. Boston Scientific Corporation $36 2 payments
  8. ASCEND Therapeutics US, LLC $25 1 payment
  9. Medline Industries, Inc. $24 1 payment
  10. Biohaven Pharmaceuticals, Inc. $23 1 payment
  11. Other $163 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,398 55 payments
  2. Education $311 5 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $393 12 payments
  2. MYRBETRIQ $221 13 payments
  3. ALTAVIVA $203 1 payment
  4. Prolia $157 8 payments
  5. EVENITY $138 7 payments
  6. Axonics $76 4 payments
  7. INTERSTIM Sacral Nerve Stimulation $55 1 payment
  8. MYFEMBREE $36 2 payments
  9. ORILISSA $35 2 payments
  10. ESTROGEL $25 1 payment
  11. Other $230 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

300

Median for Obstetrics & Gynecology: 65

Drug cost

$7,009

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

20.3%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 57 $3,680
Megestrol Acetate Generic 11 $821
Estradiol (Once Weekly) Estradiol Brand 15 $703
Raloxifene Hcl Generic 12 $329
Valacyclovir Valacyclovir Hcl Brand 15 $279
Metronidazole Generic 36 $275
Paroxetine Hcl Generic 11 $203
Sharobel Norethindrone Brand 13 $188
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 18 $140
Oxycodone Hcl Generic 36 $115

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$35,105

Medicare's payments for the services billed

Medicare patients

73

Average age 69

Services billed

394

73 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 32%
Chronic kidney disease 32%
Heart failure 29%
Cancer 29%
Depression 27%
Osteoporosis 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record